Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.
 

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

std_Portrait%20Antman11.jpg
  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. 

Join us at the next event, or view for past events by visiting the Emerging Science Series page on Professional Heart Daily.

Latest Posts

Archive for April, 2012
ESS12headerbanner.jpg

Protecting Cerebrovascular Function- From Translational 
Science to Clinical Trials

Moderators: Robert O Bonow, Elliott Antman and Robert Harrington

 

Panelists: Jeffrey Weitz, John M Murkin and Mark Clay

 

Presentation:

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial  

Jonathan P Piccini, Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC  

 

Discussion Q&A  

 

Presentation:

Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery

Ronald B Easley, Baylor Coll of Med, Houston, TX

 

Discussion Q&A 

  


Questions or Comments?

Abstract Submission
Email: support@abstractsonline.com   
Phone: 217-398-1792
General Information
Email: sessions@heart.org   
Online: scientificsessions.org
Posted by Alyson PON Editor on Apr 27, 2012 9:54 AM CDT

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

 
Moderators: 
  • Elliott Antman
  • Robert Harrington
  • Robert Bonow
Panelists:
  • John Murkin
  • Jeffrey Weitz 
  • Mark Clay

 

     
Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial
Presenter: Jonathan P. Piccini, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.
 
      Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  
Presenter: Ronald B. Easley, Baylor College of Medicine, Houston, Texas 
Posted by Alyson PON Editor on Apr 27, 2012 9:44 AM CDT

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

Presentation Topics: 
 
  1. Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial  
    Presenter: Jonathan P. Piccini, Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC
    View abstract   |   Science News Summary 
     
  2. Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  
    Presenter: Ronald B. Easley, Baylor Coll of Med, Houston, TX
    View manuscript   |   Science News Summary
more...
Posted by Alyson PON Editor on Apr 24, 2012 9:32 AM CDT

Most Recent Comments

I am intrigued by this exciting new AHA Emerging Science Series, and particularly interested to hear the discussion on the US subgroup analysis from PLATO.
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.